Table 4 Patient background of clinical events in the asymptomatic PE and asymptomatic DVT groups

Asymptomatic PE with/without DVT

Asymptomatic DVT

Total

Occurred clinical events

Not occurred clinical events

P-value

Total

Occurred clinical events

Not occurred clinical events

P-value

Clinically relevant events

n = 197

n = 25

n = 172

n = 203

n = 33

n = 170

Age (years)

65 ± 14

67 ± 14

65 ± 15

0.47

72 ± 12

74 ± 11

71 ± 12

0.28

 ≥ 75 years

58 (29.4%)

7 (28.0%)

51 (29.7%)

1.00

88 (43.3%)

17 (51.5%)

71 (41.8%)

0.34

Female

94 (47.7%)

11 (44.0%)

83 (48.3%)

0.83

151 (74.4%)

24 (72.7%)

127 (74.7%)

0.49

Body weight (kg)

62.7 ± 13.8

61.3 ± 13.5

62.9 ± 13.8

0.60

55.5 ± 11.6

51.0 ± 10.5

56.3 ± 11.8

0.017

 < 50 kg

33 (16.8%)

7 (28.0%)

26 (15.1%)

0.15

63 (31.0%)

15 (45.5%)

48 (28.2%)

0.06

CrCL (mL/minute)

84.5 ± 33.8

83.7 ± 37.3

84.7 ± 33.3

0.90

72.9 ± 28.4

67.8 ± 31.4

73.9 ± 27.7

0.26

 < 50 mL/minute

29 (14.7%)

4 (16.0%)

25 (14.5%)

0.77

47 (23.2%)

13 (39.4%)

34 (20.0%)

0.025

Diabetes mellitus

27 (13.7%)

1 (4.0%)

26 (15.1%)

0.21

28 (13.8%)

3 (9.1%)

25 (14.7%)

0.58

Chronic heart and lung disease

7 (3.6%)

3 (12.0%)

4 (2.3%)

0.045

9 (4.4%)

3 (9.1%)

6 (3.5%)

0.16

Active cancer

54 (27.4%)

14 (56.0%)

40 (23.3%)

0.001

55 (27.1%)

18 (54.5%)

37 (21.8%)

< 0.001

D-dimer (µg/mL)

9.3 (5.3–17.5)

9.5 (6.3–16.1)

9.1 (5.1–17.5)

0.65

6.6 (2.9–11.9)

7.1 (3.4–11.1)

6.4 (2.7–12.3)

0.40

Initial rivaroxaban treatment

Treatment duration, days

Median (IQR)

361 (165–630)

222 (107–319)

406 (173–647)

0.002

106 (68–259)

170 (100–388)

99 (55–223)

0.030

Recurrence or aggravation of symptomatic VTE

n = 197

n = 6

n = 191

n = 203

n = 6

n = 197

Age (years)

65 ± 14

60 ± 17

65 ± 14

0.35

70 ± 12

72 ± 10

70 ± 12

0.81

 ≥ 75 years

58 (29.4%)

1 (16.7%)

57 (29.8%)

0.67

134 (42.1%)

3 (37.5%)

131 (42.3%)

1.00

Female

94 (47.7%)

4 (66.7%)

90 (47.1%)

0.43

220 (69.2%)

6 (75.0%)

214 (69.0%)

1.00

Body weight (kg)

62.7 ± 13.7

70.0 ± 14.0

62.4 ± 13.7

0.18

57.3 ± 12.6

55.7 ± 13.5

57.3 ± 12.6

0.72

 < 50 kg

33 (16.8%)

1 (16.7%)

32 (16.8%)

1.00

90 (28.3%)

4 (50.0%)

86 (27.7%)

0.23

CrCL (mL/minute)

84.5 ± 33.8

114.4 ± 44.0

83.6 ± 33.1

0.027

72.9 ± 28.4

67.5 ± 33.3

73.1 ± 28.3

0.64

 < 50 mL/minute

29 (14.9%)

0 (0.0%)

29 (15.3%)

0.59

69 (22.0%)

3 (37.5%)

66 (21.6%)

0.38

Diabetes mellitus

27 (13.7%)

0 (0.0%)

27 (14.1%)

1.00

41 (12.9%)

1 (12.5%)

40 (12.9%)

1.00

Chronic heart and lung disease

7 (3.6%)

0 (0.0%)

7 (3.7%)

1.00

17 (5.4%)

1 (12.5%)

16 (5.2%)

0.36

Active cancer

51 (25.9%)

1 (16.7%)

50 (26.2%)

1.00

75 (23.6%)

2 (25.0%)

73 (23.6%)

1.00

D-dimer (µg/mL)

9.3 (5.3–17.5)

8.0 (5.1–9.3)

9.3 (5.2–17.5)

0.30

7.9 (3.5–14.2)

10.7 (3.1–16.5)

7.8 (3.5–14.2)

0.60

Initial rivaroxaban treatment

Treatment duration, days

Median (IQR)

361 (165–630)

216 (80–477)

362 (166–630)

0.37

106 (68–259)

170 (147–321)

173 (85–514)

0.82

Major bleeding

n = 197

n = 4

n = 193

n = 203

n = 6

n = 197

Age (years)

65 ± 14

55 ± 19

65 ± 14

0.16

70 ± 12

72 ± 10

70 ± 12

0.72

 ≥ 75 years

58 (29.4%)

0 (0.0%)

58 (30.1%)

0.32

134 (42.1%)

3 (37.5%)

131 (42.3%)

1.00

Female

94 (47.7%)

3 (75.0%)

91 (47.2%)

0.35

220 (69.2%)

5 (62.5%)

215 (69.4%)

0.71

Body weight (kg)

62.7 ± 13.8

54.9 ± 13.5

62.8 ± 13.8

0.26

57.3 ± 12.6

54.3 ± 8.5

57.4 ± 12.7

0.50

 < 50 kg

33 (16.8%)

2 (50.0%)

31 (16.1%)

0.13

90 (28.3%)

1 (12.5%)

89 (28.7%)

0.45

CrCL (mL/minute)

84.5 ± 33.8

111.9 ± 58.6

84.0 ± 33.1

0.10

72.9 ± 28.4

63.1 ± 18.7

73.2 ± 28.6

0.39

 < 50 mL/minute

29 (14.9%)

0 (0.0%)

29 (15.2%)

1.00

69 (22.0%)

2 (25.0%)

67 (21.9%)

0.69

Diabetes mellitus

27 (13.7%)

0 (0.0%)

27 (14.0%)

1.00

41 (12.9%)

1 (12.5%)

40 (12.9%)

1.00

Chronic heart and lung disease

7 (3.6%)

1 (25.0%)

6 (3.1%)

0.14

17 (5.4%)

0 (0.0%)

17 (5.5%)

1.00

Active cancer

54 (27.4%)

0 (0.0%)

54 (28.0%)

0.58

75 (23.6%)

4 (50.0%)

71 (22.9%)

0.09

D-dimer (µg/mL)

9.3 (5.3–17.5)

10.3 (9.5–15.4)

9.1 (5.2–17.5)

0.53

7.9 (3.5–14.2)

7.1 (2.7–23.7)

7.9 (3.6–14.2)

0.96

Initial rivaroxaban treatment

Treatment duration, days

Median (IQR)

361 (165–630)

236 (41–371)

362 (168–631)

0.18

106 (68–259)

294 (38–595)

173 (86–514)

0.92